Presentation is loading. Please wait.

Presentation is loading. Please wait.

Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial  R.S Keresztes, MD, J.L Port, MD, M.W Pasmantier,

Published byAlbina Sacco Modified over 5 years ago

Similar presentations

Presentation on theme: "Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial  R.S Keresztes, MD, J.L Port, MD, M.W Pasmantier,"— Presentation transcript:

1 Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial  R.S Keresztes, MD, J.L Port, MD, M.W Pasmantier, MD, R.J Korst, MD, N.K Altorki, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 126, Issue 5, Pages (November 2003) DOI: /S (03)

2 Figure 1 Kaplan-Meier survival for all patients.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (03) )

3 Figure 2 Kaplan-Meier survival for patients undergoing resection.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (03) )

Download ppt "Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial  R.S Keresztes, MD, J.L Port, MD, M.W Pasmantier,"

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Previous coronary stents do not increase early and long-term adverse outcomes in patients undergoing off-pump coronary artery bypass grafting: A propensity-matched.

Previous coronary stents do not increase early and long-term adverse outcomes in patients undergoing off-pump coronary artery bypass grafting: A propensity-matched.
Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma  Kimberly S. Grant, MD,

Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma  Kimberly S. Grant, MD,
Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal.

Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal.
Stephen R. Broderick, MD, MPHS 

Stephen R. Broderick, MD, MPHS 
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.
Balancing curability and unnecessary surgery in the context of computed tomography screening for lung cancer  Raja Flores, MD, Thomas Bauer, MD, Ralph.

Balancing curability and unnecessary surgery in the context of computed tomography screening for lung cancer  Raja Flores, MD, Thomas Bauer, MD, Ralph.
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer  Marco Alifano, MD, PhD, Pierre.

Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer  Marco Alifano, MD, PhD, Pierre.
Don't look now! Risk stratify first

Don't look now! Risk stratify first
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Puja Gaur, MD, Tsuyoshi Kaneko, MD, Siobhan McGurk, BS, James D

Puja Gaur, MD, Tsuyoshi Kaneko, MD, Siobhan McGurk, BS, James D
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: A population-based Scandinavian Sarcoma Group study of 106 patients  Björn.

Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: A population-based Scandinavian Sarcoma Group study of 106 patients  Björn.
Preoperative mediastinoscopic assessment of N factors and the need for mediastinal lymph node dissection in T1 lung cancer  Takeshi Funatsu, MD, Yoshito.

Preoperative mediastinoscopic assessment of N factors and the need for mediastinal lymph node dissection in T1 lung cancer  Takeshi Funatsu, MD, Yoshito.

Similar presentations

Ads by Google